Patients with metastatic triple-negative breast cancer (mTNBC) (defined by a lack of tumor-cell expression of the estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 [HER2]) have unfavorable outcomes [3,4]. The gene discussed is ERBB2; the disease is neoplasm.